SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Psoriasis/Chronic Inflammation
An SI Board Since February 2001
Posts SubjectMarks Bans
631 42 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
506Chemical cousin of anti-anxiety drugs holds promise for psoriasis treatment EuJohn McCarthy-12/9/2004
505[ Triad/Novartis/p38 ] Message 20839619scaram(o)uche-12/8/2004
504Proc Natl Acad Sci U S A. 2004 Nov 19; [Epub ahead of print] SMAC/Diablo-dependscaram(o)uche-11/24/2004
503Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal aIcebrg-10/23/2004
502[ CTLA4Ig/BMY ] Phase III Clinical Trial Results of Investigational Biologic Abscaram(o)uche-10/17/2004
501focusing on the origin of "side effects", from an anti-inflammatory pescaram(o)uche-9/15/2004
500Life Sci. 2004 Aug 6;75(12):1513-22. Ajulemic acid: A novel cannabinoid produscaram(o)uche-7/9/2004
499Full text freebie from JCI: "Recent insights into the immunopathogenesis otuck-6/16/2004
498J Rheumatol. 2004 Jun;31(6):1143-51. Blood Pressure Destabilization and Edemascaram(o)uche-6/2/2004
497Oral simvastatin treatment in relapsing-remitting multiple sclerosis Timothy VoIcebrg-5/14/2004
496[Psoriasis and systemic treatments for it increase lymphoma?] the-scientist.comtuck-4/29/2004
495lousy release..... Br J Dermatol. 1998 Sep;139(3):390-5. The antipsoriatic ascaram(o)uche-4/29/2004
494BIIB / BG-12 Phase II Psoriasis results - CAMBRIDGE, Mass., SAN DIEGO, Calif. anigel bates-4/29/2004
493Cancer Drug Relieves Severe Psoriasis Wed Apr 21 09:11:29 2004 By Will BoggsJohn McCarthy-4/21/2004
492J Physiol Pharmacol. 2003 Dec;54 Suppl 4:165-82. Role of COX inhibition in pascaram(o)uche-4/14/2004
491Clin Gastroenterol Hepatol. 2004 Apr;2(4):290-5. A randomized, controlled comscaram(o)uche-4/7/2004
490March 29, 2004 Astralis Initiates U.S. Phase II Clinical Trial for Psoraxinesim1-4/2/2004
489From amgn first r&d day: <i>However, Amgen said an early-stage arthrikeokalani'nui-3/23/2004
488Genentech and XOMA Announce Results Of Phase II Study of Raptiva(TM) in Psoriatiscaram(o)uche-3/22/2004
487They are now a wholly-owned sub of a Croatian company, PLIVA. Any coincidence tscaram(o)uche-3/21/2004
486Compugen Discovers Novel Soluble CD40 Protein CORAL GABLES, Fla.--(BUSINESS WIRnigel bates-3/1/2004
485DOMANTIS AND PEPTECH dAbs SHOW SUPERIOR POTENCY COMPARED WITH MARKETED PRODUCTS nigel bates-2/28/2004
484[ excerpt from today's Amgen release ] Patients withdrawn from ENBREL treatscaram(o)uche-2/7/2004
483[ Allergan/once daily oral retinoid ] New Long-Term Studies Demonstrate Effectiscaram(o)uche-2/7/2004
482FEBRUARY 3, 2004 - 02:30 ET Elan and Biogen Idec Announce Initiation of ANTEGRErusset-2/3/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News